University of Hertfordshire

Natural chalcones as dual inhibitors of HDACs and NF-κB

Research output: Contribution to journalArticlepeer-review

  • B. Orlikova
  • M. Schnekenburger
  • Mire Zloh
  • F. Golais
  • M. Diederich
  • D. Tasdemir
View graph of relations
Original languageEnglish
Pages (from-to)797-805
Number of pages9
JournalOncology Reports
Volume28
Issue3
Early online date15 Jun 2012
DOIs
Publication statusPublished - 2012

Abstract

Histone deacetylase enzymes (HDACs) are emerging as a promising biological target for cancer and inflammation. Using a fluorescence assay, we tested the in vitro HDAC inhibitory activity of twenty-one natural chalcones, a widespread group of natural products with well-known anti-inflammatory and antitumor effects. Since HDACs regulate the expression of the transcription factor NF-κB, we also evaluated the inhibitory potential of the compounds on NF-κB activation. Only four chalcones, isoliquiritigenin (no. 10), butein (no. 12), homobutein (no. 15) and the glycoside marein (no. 21) showed HDAC inhibitory activity with IC50 values of 60-190 µM, whereas a number of compounds inhibited TNFα-induced NF-κB activation with IC50 values in the range of 8-41 µM. Interestingly, three chalcones (nos. 10, 12 and 15) inhibited both TNFα-induced NF-κB activity and total HDAC activity of classes I, II and IV. Molecular modeling and docking studies were performed to shed light into dual activity and to draw structure-activity relationships among chalcones (nos. 1-21). To the best of our knowledge this is the first study that provides evidence for HDACs as potential drug targets for natural chalcones. The dual inhibitory potential of the selected chalcones on NF-κB and HDACs was investigated for the first time. This study demonstrates that chalcones can serve as lead compounds in the development of dual inhibitors against both targets in the treatment of inflammation and cancer.

Notes

Article available on open access at http://dx.doi.org/10.3892/or.2012.1870

ID: 1456034